Published in J Clin Exp Hepatol on October 21, 2016
Primary biliary cirrhosis. Hepatology (2009) 5.35
EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol (2009) 4.45
Prognosis in primary biliary cirrhosis: model for decision making. Hepatology (1989) 3.83
Primary biliary cirrhosis. N Engl J Med (1996) 3.51
Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression. J Lipid Res (1996) 3.36
Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. Gastroenterology (2014) 3.29
Primary biliary cirrhosis in monozygotic and dizygotic twins: genetics, epigenetics, and environment. Gastroenterology (2004) 2.64
Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology (2014) 2.40
Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology (2008) 2.36
Increased prevalence of primary biliary cirrhosis near Superfund toxic waste sites. Hepatology (2006) 2.08
Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. The UDCA-PBC Study Group. Hepatology (1999) 2.05
Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology (2006) 1.96
Bile acids induce inflammatory genes in hepatocytes: a novel mechanism of inflammation during obstructive cholestasis. Am J Pathol (2010) 1.91
Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol (2012) 1.84
Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. J Hepatol (2011) 1.82
The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology (2005) 1.67
Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Aliment Pharmacol Ther (2010) 1.52
Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis? Lancet (1987) 1.52
Additive improvement induced by bezafibrate in patients with primary biliary cirrhosis showing refractory response to ursodeoxycholic acid. J Gastroenterol Hepatol (2011) 1.49
Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology (2009) 1.45
Cholestasis induces major histocompatibility complex class I expression in hepatocytes. Gastroenterology (1992) 1.43
The immunobiology and pathophysiology of primary biliary cirrhosis. Annu Rev Pathol (2013) 1.41
Primary biliary cirrhosis. Lancet (2015) 1.27
Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial. Gastroenterology (1999) 1.16
IL-12/Th1 and IL-23/Th17 biliary microenvironment in primary biliary cirrhosis: implications for therapy. Hepatology (2014) 1.15
Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. Am J Gastroenterol (2010) 1.14
Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: a three-year randomized trial. Hepatology (2005) 1.12
Ursodeoxycholic acid and bile-acid mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action. Clin Res Hepatol Gastroenterol (2012) 1.09
Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center. Hepatology (2001) 1.09
Nuclear DNA fragmentation and expression of Bcl-2 in primary biliary cirrhosis. Hepatology (1997) 1.07
The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology (2000) 1.06
A prospective randomized controlled study of long-term combination therapy using ursodeoxycholic acid and bezafibrate in patients with primary biliary cirrhosis and dyslipidemia. Am J Gastroenterol (2015) 1.05
Ursodeoxycholic acid protects hepatocytes against oxidative injury via induction of antioxidants. Biochem Biophys Res Commun (1999) 1.04
Ligand-independent activation of the glucocorticoid receptor by ursodeoxycholic acid. Repression of IFN-gamma-induced MHC class II gene expression via a glucocorticoid receptor-dependent pathway. J Immunol (1996) 1.04
Fenofibrate for patients with asymptomatic primary biliary cirrhosis. World J Gastroenterol (2004) 1.02
Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology (1990) 1.02
Novel therapeutic targets in primary biliary cirrhosis. Nat Rev Gastroenterol Hepatol (2015) 1.01
Demographic, lifestyle, medical and familial factors associated with primary biliary cirrhosis. J Hepatol (2010) 1.01
Abnormal expression of anion exchanger genes in primary biliary cirrhosis. Gastroenterology (1993) 1.00
Primary biliary cirrhosis: Pathophysiology, clinical presentation and therapy. World J Hepatol (2015) 0.99
Fenofibrate treatment in patients with primary biliary cirrhosis. Am J Gastroenterol (2002) 0.98
Ongoing activation of autoantigen-specific B cells in primary biliary cirrhosis. Hepatology (2014) 0.98
Transplantation trends in primary biliary cirrhosis. Clin Gastroenterol Hepatol (2007) 0.98
Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid. Liver (1999) 0.96
Oral budesonide in the treatment of patients with primary biliary cirrhosis with a suboptimal response to ursodeoxycholic acid. Hepatology (2000) 0.96
Immunosuppression affects the rate of recurrent primary biliary cirrhosis after liver transplantation. Liver Transpl (2004) 0.93
Combination of ursodeoxycholic acid and glucocorticoids upregulates the AE2 alternate promoter in human liver cells. J Clin Invest (2008) 0.92
Pharmacokinetics and pharmacodynamic action of budesonide in early- and late-stage primary biliary cirrhosis. Hepatology (2003) 0.90
Varices in early histological stage primary biliary cirrhosis. J Clin Gastroenterol (2011) 0.89
Fibrates and cholestasis. Hepatology (2015) 0.86
Bezafibrate treatment of primary biliary cirrhosis following incomplete response to ursodeoxycholic acid. J Clin Gastroenterol (2010) 0.85
B-cell depletion with rituximab in patients with primary biliary cirrhosis refractory to ursodeoxycholic acid. Am J Gastroenterol (2013) 0.84
Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy. J Dig Dis (2012) 0.83
Multidrug resistance3 is in situ detected in the liver of patients with primary biliary cirrhosis, and induced in human hepatoma cells by bezafibrate. Hepatol Res (2004) 0.82
Combination therapy of fenofibrate and ursodeoxycholic acid in patients with primary biliary cirrhosis who respond incompletely to UDCA monotherapy: a meta-analysis. Drug Des Devel Ther (2015) 0.82
Bezafibrate normalizes alkaline phosphatase in primary biliary cirrhosis patients with incomplete response to ursodeoxycholic acid. Liver Int (2013) 0.82
Diagnosis of primary biliary cirrhosis. Best Pract Res Clin Gastroenterol (2011) 0.82
Cytotoxic T-lymphocyte associated antigen-4 gene polymorphisms and primary biliary cirrhosis: a systematic review. J Gastroenterol Hepatol (2012) 0.80
Potential Roles for Infectious Agents in the Pathophysiology of Primary Biliary Cirrhosis: What's New? Curr Infect Dis Rep (2013) 0.79
Effect of ursodeoxycholic acid on methionine adenosyltransferase activity and hepatic glutathione metabolism in rats. Gut (2002) 0.79
Advances in pharmacotherapy for primary biliary cirrhosis. Expert Opin Pharmacother (2014) 0.78
HLA-DR polymorphism and primary biliary cirrhosis: evidence from a meta-analysis. Arch Med Res (2014) 0.78
Old and novel therapies for primary biliary cirrhosis. Semin Liver Dis (2014) 0.77
Fibrate treatment for primary biliary cirrhosis. Curr Opin Gastroenterol (2014) 0.77
Preventive administration of UDCA after liver transplantation for primary biliary cirrhosis is associated with a lower risk of disease recurrence. J Hepatol (2015) 0.76
Proposed therapies in primary biliary cholangitis. Expert Rev Gastroenterol Hepatol (2016) 0.76